Click Here to
receive daily
reports of the
TOP PICKS
OR
your personal
stock choices

STOCKCHASE

What the experts are saying!
This site compiles comments that experts make about stocks while on public TV shows.

There are 3 registered members and 55 guests viewing the site. Follow us on Twitter Rss Top Picks FeedRss Daily Feed

Biomira
Symbol: BRA-T
Active: N
Sector: biotechnology/pharmaceutical
Notes:Breast cancer applications
Last Price: 0.530
Last Price Date: 2007-12-10 21:27:23
Globe 200 day average

Experts who have talked about Biomira

SELL3.880David ChapmanNot a fan of biotech stocks. Difficult to read with all the little points of approval or non-approval. With the big spike, don't buy.2004-12-03
TOP PICK67.580Alison DeansThe entire energy sector is an interesting play. There has been a shrinkage of capacity in the last several years.2004-04-23
DON'T BUY1.850Ross HealyOutlook is anybody's guess. No earnings.2003-01-16
DON'T BUY6.280Ray SteeleWill take a while. Prefers Isotechnica,2002-01-16
BUY on WEAKNESS6.750Brian Acker, CARISKY. No earnings. Treat as a trading stock between $5 and $7.2001-12-28
BUY7.000Peter BriegerGood long term investment, but prefers MDS.2001-11-14
DON'T BUY6.000Glenn Paradis, BA, CFAGreat product, but company has had problems.2001-10-31
DON'T BUY6.300Brian Acker, CABiotechs out of favour. Has broken $6.40. Next level is $3.90.2001-09-19
WAIT12.640John ZechnerTaking a long time to get to market.2001-05-25
DON'T BUY11.080John ZechnerDoesn't have top line growth. Some products in 3rd phase. Speculative.2001-05-18
BUY on WEAKNESS12.960Glenn Paradis, BA, CFAIn phase 3 and has partnered with Merk.2001-05-04
BUY10.380David BaskinSmart mngmnt. Good sector. Big litigation risk re: patents/class action suits in pharmaceuticals.2001-04-09
BUY12.400Glenn Paradis, BA, CFAGood company. Drugs in 3rd phase. Short term should do well. Getting a new partner2001-02-01
BUY on WEAKNESS12.850Steven MisenerA very active/volatile stock. Lots of press2001-01-23
DON'T BUY13.000Fred KetchenDifficult to select which bio company but prefers BioChem or a fund2000-11-21
DON'T BUY15.000Ross HealyNo earnings Speculative play Loss because of research costs2000-11-08
DON'T BUY14.000Robert FloydNews driven. Have to have good balance sheets2000-11-01
STRONG BUY14.000Glenn Paradis, BA, CFAUndervalued. Market waiting for a partner & test results. Should be there by year end2000-10-13

Privacy Policy